Healthcare provider profile · identity verified

Osama Mohamed, M.D.

Family Practice · LANCASTER, CA · NPI 1710247044

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	298	120
Lisinopril	Lisinopril	233	86
Amlodipine Besylate	Amlodipine Besylate	201	75
Metformin Hcl	Metformin Hcl	201	76
Rosuvastatin Calcium	Rosuvastatin Calcium	128	50
Levothyroxine Sodium	Levothyroxine Sodium	127	41
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	111	28
Omeprazole	Omeprazole	106	46
Glipizide	Glipizide	102	37
Losartan Potassium	Losartan Potassium	98	38
Simvastatin	Simvastatin	87	28
Terazosin Hcl	Terazosin Hcl	79	27
Albuterol Sulfate Hfa	Albuterol Sulfate	77	44
Azelastine Hcl	Azelastine Hcl	65	31
Gabapentin	Gabapentin	65	27
Atenolol	Atenolol	62	20
Naproxen	Naproxen	62	42
Ibuprofen	Ibuprofen	61	25
Pantoprazole Sodium	Pantoprazole Sodium	60	20
Ipratropium Bromide	Ipratropium Bromide	59	43
Jardiance	Empagliflozin	56	21
Metoprolol Tartrate	Metoprolol Tartrate	54	22
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	53	22
Pioglitazone Hcl	Pioglitazone Hcl	52	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	51	18
Spiriva Respimat	Tiotropium Bromide	51	17
Hydrochlorothiazide	Hydrochlorothiazide	49	18
Metformin Hcl Er	Metformin Hcl	49	20
Tamsulosin Hcl	Tamsulosin Hcl	48	19
Chlorthalidone	Chlorthalidone	45	17
Pradaxa	Dabigatran Etexilate Mesylate	45	18
Wixela Inhub	Fluticasone Propion/Salmeterol	44	15
Furosemide	Furosemide	43	22
Ozempic	Semaglutide	43	13
Potassium Chloride	Potassium Chloride	43	15
Trazodone Hcl	Trazodone Hcl	43	16
Clopidogrel	Clopidogrel Bisulfate	38	11
Mirtazapine	Mirtazapine	38	suppressed
Allopurinol	Allopurinol	36	11
Bisoprolol Fumarate	Bisoprolol Fumarate	35	13
Clonidine Hcl	Clonidine Hcl	35	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	34	12
Meloxicam	Meloxicam	33	14
Alendronate Sodium	Alendronate Sodium	31	14
Famotidine	Famotidine	24	12
Humulin N	Insulin Nph Human Isophane	24	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	23	12
Benazepril Hcl	Benazepril Hcl	22	suppressed
Metoprolol Succinate	Metoprolol Succinate	22	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Eliquis	Apixaban	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	19	suppressed
Lactulose	Lactulose	19	12
Colchicine	Colchicine	18	suppressed
Finasteride	Finasteride	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	14
Spironolactone	Spironolactone	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Terbinafine Hcl	Terbinafine Hcl	16	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	16	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	15	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	14	14
Alvesco	Ciclesonide	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Scopolamine	Scopolamine	13	suppressed
Sertraline Hcl	Sertraline Hcl	13	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	11
Ezetimibe	Ezetimibe	11	suppressed
Mupirocin	Mupirocin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error